INMD
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency (\'RF\') technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.
InMode Ltd. (INMD) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Growth (D+). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | B (3.3) | D+ (1.8) | B- (3.0) | B- (2.9) | C+ (2.6) | C+ (2.7) |
| 2026-11-05 | B (3.3) | D+ (1.8) | B- (3.0) | B- (2.9) | C+ (2.7) | C+ (2.7) |
| 2026-10-29 | B (3.3) | D+ (1.7) | B- (3.0) | C+ (2.6) | C+ (2.7) | C+ (2.6) |
| 2026-10-22 | B (3.3) | D+ (1.8) | B- (3.0) | C+ (2.5) | C+ (2.6) | C+ (2.6) |
| 2026-10-15 | B (3.3) | D+ (1.8) | B- (3.0) | C+ (2.6) | C+ (2.6) | C+ (2.7) |